Active Biotech AB (publ) (FRA:BTP)

Market Cap	8.03M -4.6%
Revenue (ttm)	n/a
Net Income	-3.03M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,250
Open	0.2500
Previous Close	0.2500
Day's Range	0.2500 - 0.2500
52-Week Range	0.1600 - 0.9900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BTP

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error